Table 2.

Patient characteristics and clinical outcomes of real-life studies included

Source	Study design		Baseline characteristicsa				Effectiveness
	Number of patients	Treatment duration	Age (yr)	FEV1 (%pred)	Serum IgE level (IU/mL)	Baseline ICS use (μg/d)	Clinical outcomes
Molimard et al30	147	n/a	46.5	n/a	283.4	3,071.2b	Patients with 5 mo of follow-up or longer:  Annual rate of exacerbations requiring OCS: 62% reduction.  Use of OCS: 48.1% reduction or discontinuation.  Annual rate of emergency visits: 65% reduction.  Annual rate of hospitalizations: 29% reduction.
Brusselle et al31	158	52 wk	48.2	56.5	613.9	n/a	Treatment effectiveness (in ITT):  % patient improving in 2005 GINA classification: 31%.  Magnitude of FEV1 improvement: 12.23%.a  % patient improving in AQLQ total score >0.5: 84.4%.  % PERSIST severe exacerbationc free: 65.6%.  Number of health care visits: reduction of 1.49 visits.a
Barnes et al32	136	n/a	41.3	62.9	n/a	n/a	Daily OCS dose: 25.6% reduction.  Number of asthma exacerbation: 1.7 events/yr vs 3.67 events/yr at baseline.a  Amount of FEV1 improvement: 12.8%.a
Cazzola et al33	142	1 yr	49.6	64.8	297.4	2,224.7	Annual exacerbation rate: 78% reduction.  Annual emergency visits rate: 87% reduction.  Annual hospitalization rate: 96% reduction.  ICS dose (patients with over 12 mo of treatment): 1,604.6 μg/d.a
Braunstahl et al34	943	2 yr	45	n/a	323.1	n/a	Proportion of patients with no clinically significant exacerbations: 54.1% (12 mo) and 67.3% (24 mo) vs 6.8% at baseline.  Proportion of patients taking OCS (in ITT): 16.1% (12 mo) and 14.2% (24 mo) vs 28.6% at baseline.  Total daily OCS dose: 7.7 mg (12 mo) and 5.8 mg (24 mo) vs 15.5 mg at baseline.a
Deschildre et al38	104	52 wk	11.9	88	1,125	703d	Asthma control:  % children achieving good control level (based on GINA criteria): 67% vs 0% at baseline.  Exacerbation rate: 72% reduction.  Health care utilization: 88.5% reduction in hospital admissions.  ICS dose: reduction of 212 μg,a,d equivalent to a 30% reduction.
Odajima et al39	38	24 wk	10.7	90.3	335.5	469.7	Asthma control:  Geometric mean of serum free IgE levels:  15.6 ng/mL (vs 778.7 ng/mL at baseline).a  Asthma exacerbation rate: 69.2% reduction.  Hospitalization rate: 78.2% reduction.  % patients reduced controller medication: 28.9%.

Notes:

^aData are shown as mean;

^bequivalent BDP;

^cPERSIST severe exacerbations were those that met the following criteria: the patient required a systemic corticosteroid, or the patient required an emergency room visit or hospitalization for the exacerbation;

^dfluticasone propionate equivalent.

Abbreviations: AQLQ, asthma quality of life questionnaire; BDP, beclomethasone dipropionate; FEV₁, forced expiratory volume in 1 second; GINA, Global Initiative for Asthma; ICS, inhaled corticosteroid; IgE, immunoglobulin E; ITT, intent to treat; OCS, oral corticosteroids; n/a, not applicable; wk, weeks; yr, years; mo, months.